Angeion's Sentinel ICDs (implantable cardioverter defibrillators) with extended lifetime:
This article was originally published in Clinica
Executive Summary
Angeion has received premarket approval from the FDA for its Sentinel series of implantable cardioverter defibrillators. The series consists of ICD models 2000, 2010, 2011 and 2012, the Angeflex lead system, an ICD programming system and the external defibrillation test system. The Minneapolis, Minnesota-based company says a new dual battery system gives the products an extended lifetime of 10 years.
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.